TAK - Takeda fails in second Phase 3 trial for CPF therapy Alofisel
2023-10-18 14:00:05 ET
More on Takeda
- Takeda: Innovative But Volatile, Fairly Priced For The Risk (Downgrade)
- Takeda Pharmaceutical Company Limited (TAK) Q1 2023 Earnings Call Transcript
- Takeda to voluntarily pull lung cancer drug Exkivity from U.S. market
- Takeda Entyvio subcutaneous version wins FDA nod
- Seeking Alpha’s Quant Rating on Takeda Pharmaceutical
For further details see:
Takeda fails in second Phase 3 trial for CPF therapy Alofisel